×
About 883 results

ALLMedicine™ Anaplastic Astrocytoma Center

Research & Reviews  292 results

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
https://clinicaltrials.gov/ct2/show/NCT02796261

Jan 21st, 2022 - This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatmen...

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT03022578

Jan 20th, 2022 - PRIMARY OBJECTIVES: I. Determine the disease control rate at 6 months in patients with recurrent glioblastoma or isocitrate dehydrogenase (IDH)-wildtype anaplastic astrocytoma treated with Laser Interstitial Thermal Therapy (LITT) at recurrence, f...

Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756697
BMC Neurology; Metz G, Jayamanne D et. al.

Jan 15th, 2022 - The impact of near-total resection of IDH-mutated anaplastic glioma (IDHmutAG) is well-established but there remains uncertainty of benefit in tumours of the insular cortex where the extent of safe resection may be limited. This study aimed to ass...

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04047303

Jan 4th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...

Hormone exposure and its suppressive effect on risk of high-grade gliomas among patient...
https://doi.org/10.1016/j.jocn.2021.10.029
Journal of Clinical Neuroscience : Official Journal of Th... Lopez-Garcia CA, Lopez-Rivera V et. al.

Dec 6th, 2021 - Prior reports demonstrate the expression of estrogen and progesterone receptors in high-grade gliomas (HGGs), but the relationship between hormone receptor-positive disease and risk of HHGs in patients with breast cancer (BC) remains uncharacteriz...

see more →

Drugs  15 results see all →

Clinicaltrials.gov  31 results

Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients
https://clinicaltrials.gov/ct2/show/NCT02796261

Jan 21st, 2022 - This study will consist of 4 study periods of up to 50 months in total, consisting of: Screening Period - A maximum screening duration of 4 weeks. Treatment Period - Treatment Arm A up to 24 months; Treatment Arm B up to 12 months. End of Treatmen...

Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT03022578

Jan 20th, 2022 - PRIMARY OBJECTIVES: I. Determine the disease control rate at 6 months in patients with recurrent glioblastoma or isocitrate dehydrogenase (IDH)-wildtype anaplastic astrocytoma treated with Laser Interstitial Thermal Therapy (LITT) at recurrence, f...

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT04047303

Jan 4th, 2022 - CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects with progressive o...

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
https://clinicaltrials.gov/ct2/show/NCT01386710

Oct 28th, 2021 - The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of tumors also exhibits the most aggressive behavior, resulting in median...

Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02022644

Oct 27th, 2021 - High grade gliomas (HGG) are the most common brain tumor in adults, with 15,000 new cases/year in the USA. Despite progress made using combination therapies including surgery, radiation and/or chemotherapy, the treatment of HGG remains challenging...

see more →

News  14 results

Carboxyamidotriazole Orotate Shows Promising Activity in Brain Cancers
https://www.onclive.com/view/carboxyamidotriazole-orotate-shows-promising-activity-in-brain-cancers

Oct 6th, 2021 - Elena Pentsova, MD Carboxyamidotriazole orotate (CTO) in combination with temozolomide (Temodar), with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma (GBM) or anaplastic gl...

HER2-Specific CAR T Cells Induce Early Efficacy Without Dose-Limiting Toxicities in Pediatric CNS Tumors
https://www.onclive.com/view/her2-specific-car-t-cells-induce-early-efficacy-without-dose-limiting-toxicities-in-pediatric-cns-tumors

Aug 6th, 2021 - Repetitive locoregional infusion of HER2-specific CAR T cells did not induce any dose-limiting toxicities, according to findings from an interim analysis of the ongoing phase 1 BrainChild-01 trial (NCT03500991) that were published in Nature Medici...

Toca 511 Shows Promise in High-Grade Glioma
https://www.onclive.com/view/toca-511-shows-promise-in-highgrade-glioma

Dec 20th, 2020 - Timothy Cloughesy, MD The gene for an anticancer drug was successfully transduced in high-grade gliomas, according to data from a phase I trial of Toca 511 presented at the 2016 Society for Neuro-Oncology Annual Meeting. Additionally, the median ...

Investigators Hope Glioma Trial of Eflornithine Will Clinch Approval
https://www.onclive.com/view/investigators-hope-glioma-trial-of-eflornithine-will-clinch-approval

Dec 5th, 2020 - Victor A. Levin, MD Eflornithine (α-Difluoromethylornithine) has been investigated for over 30 years as a potential neuro-oncology agent and shown activity against recurrent gliomas, but it has not gained approval as a therapy option for patients...

Dr. Kumthekar Discusses Frontline Therapy for Anaplastic Astrocytoma
https://www.onclive.com/view/dr-kumthekar-discusses-frontline-therapy-for-anaplastic-astrocytoma

Dec 4th, 2020 - Priya U. Kumthekar, MD, assistant professor of neurology and medicine, Northwestern University Feinberg School of Medicine, discusses frontline therapy for patients with anaplastic astrocytoma. The standard frontline treatment of this patient pop...

see more →

Patient Education  1 results see all →